Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents
Yıl: 2021 Cilt: 32 Sayı: 1 Sayfa Aralığı: 19 - 24 Metin Dili: İngilizce DOI: 10.14744/scie.2020.24482 İndeks Tarihi: 17-06-2021
Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents
Öz: Objective: Biologic agents can provide effective control of disease activity in patients withchronic inflammatory disease (CID), however, they are associated with an increased risk ofserious infection. The aim of this study was to investigate the risk and distribution of seriousinfection, the rate of vaccination, and the screening tests recommended in patients treatedwith biologic agents.Methods: Patients with CID who were given biologic agent therapy were retrospectivelyevaluated. Hepatitis and tuberculosis (TB) screening tests, the vaccinations administered, riskfactors for and the rate of serious infection were reviewed.Results: Of the 320 patients included in the study, 58% were male and the mean age was44.5 years (±12.2 years). The biologic agent used was infliximab in 108 patients (33.8%),adalimumab in 115 (35.9%), etanercept in 61 (19.1%), ustekinumab in 19 (5.9%), certolizumabin 9 (2.8%), golimumab in 5 (1.6%), and secukinumab in 3 (0.9%). The hepatitis B, pneumococcal,influenza, and hepatitis A vaccination rate in patients with CID was 82.9%, 12.5%,11.6%, and 4%, respectively. The tuberculin skin test was preferred for 33.4% of the patientsfor TB screening, while the QuantiFERON-TB Gold test (Qiagen NV, Hilden, Germany) wasused in 79%. A total of 25 (7.8%) cases of serious infection occurred, and the most commonsites were the respiratory tract (28%) and the urinary tract (28%). Binary logistic regressionanalysis showed that the risk of infection was significantly higher in patients who had chronicobstructive pulmonary disease (COPD) and those who used azathioprine.Conclusion: The most common sites of infection were the respiratory tract and the urinarytract, and the risk of infection was significantly higher in patients who had COPD andthose who used azathioprine. The rate of vaccination was lower than has been recommended.Awareness of hepatitis B and TB reactivation risk in patients treated with biologic agentswas greater than awareness of the risk of other infections.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data. J Adv Res 2018;15:87–93
- 2. Pecoraro V, De Santis E, Melegari A, Trenti T. The impact of immunogenicity of TNFα inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev 2017;16:564–75.
- 3. Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 2010;5:11–22.
- 4. Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy 2017;9:229–38.
- 5. Ergun T, Seckin D, Baskan Bulbul E, Onsun N, Ozgen Z, Unalan P, et al. The risk of tuberculosis in patients with psoriasis treated with anti-tumor necrosis factor agents. Int J Dermatol 2015;54:594–9.
- 6. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522–8.
- 7. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884–94
- 8. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccinepreventable illnesses. Am J Gastroenterol 2006;101:1834–40.
- 9. Ford AC, Peyrin-Biroulet L. Opportunistic infections with antitumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013;108:1268–76.
- 10. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2017;112:241–58.
- 11. CDC: Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Available at: https://www.cdc. gov/vaccines/schedules/hcp/imz/adult.html. Accessed Feb 15, 2021.
- 12. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:309–18
- 13. Parker S, Chambers White L, Spangler C, Rosenblum J, Sweeney S, Homan E, et al. A quality improvement project significantly increased the vaccination rate for immunosuppressed patients with IBD. Inflamm Bowel Dis 2013;19:1809–14.
- 14. Jung YS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, et al. Insufficient knowledge of korean gastroenterologists regarding the vaccination of patients with inflammatory bowel disease. Gut Liver 2014;8:242–7.
- 15. Gupta A, Macrae FA, Gibson PR. Vaccination and screening for infections in patients with inflammatory bowel disease: a survey of Australian gastroenterologists. Intern Med J 2011;41:462–7.
- 16. Malhi G, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, et al. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. J Crohns Colitis 2015;9:439–44.
- 17. Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O. Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study. Dig Liver Dis 2018;50:563–7.
- 18. Pham HV, Hasan I, Udaltsova N, Pham K, Abramson O, Armstrong MA, et al. Rates and Predictors of Vaccinations Among Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Agents. Dig Dis Sci 2018;63:209–17.
- 19. Al-Omar HA, Sherif HM, Mayet AY. Vaccination status of patients using anti-TNF therapy and the physicians’ behavior shaping the phenomenon: Mixed-methods approach. PLoS One 2019;14:e0223594.
- 20. Karr JR, Lu JJ, Smith RB, Thomas AC. Using Computerized Physician Order Entry to Ensure Appropriate Vaccination of Patients with Inflammatory Bowel Disease. Ochsner J 2016;16:90–5.
- 21. Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon- gamma release assay vs. tuberculin skin test. Br J Dermatol 2009;161:797–800.
- 22. Mariette X, Baron G, Tubach F, Lioté F, Combe B, Miceli-Richard C, et al. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 2012;71:1783–90.
- 23. Mrozek N, Pereira B, Soubrier M, Gourdon F, Laurichesse H. Screening of tuberculosis before biologics. Med Mal Infect 2012;42:1–4
- 24. Ichinose K, Shimizu T, Umeda M, Fukui S, Nishino A, Koga T, et al. Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010. J Immunol Res 2018;2018:6259010.
- 25. Mori S, Yoshitama T, Hidaka T, Sakai F, Hasegawa M, Hashiba Y, et al. Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One 2017;12:e0179179.
- 26. Yoo IK, Choung RS, Hyun JJ, Kim SY, Jung SW, Koo JS, et al. Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy. Yonsei Med J 2014;55:442–8.
- 27. Clay H, Volkman HE, Ramakrishnan L. Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 2008;29:283–94.
- 28. Hashimoto A, Suto S, Horie K, Fukuda H, Nogi S, Iwata K, et al. Incidence and Risk Factors for Infections Requiring Hospitalization, Including Pneumocystis Pneumonia, in Japanese Patients with Rheumatoid Arthritis. Int J Rheumatol 2017;2017:6730812.
- 29. Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 2014;127:1208–32.
- 30. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;2011:CD008794.
- 31. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2011;63:1479–85.
- 32. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50:552–62.
- 33. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014;66:990–7.
| APA | Okay G, Biberci Keskin E (2021). Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. , 19 - 24. 10.14744/scie.2020.24482 |
| Chicago | Okay Gulay,Biberci Keskin Elmas Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. (2021): 19 - 24. 10.14744/scie.2020.24482 |
| MLA | Okay Gulay,Biberci Keskin Elmas Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. , 2021, ss.19 - 24. 10.14744/scie.2020.24482 |
| AMA | Okay G,Biberci Keskin E Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. . 2021; 19 - 24. 10.14744/scie.2020.24482 |
| Vancouver | Okay G,Biberci Keskin E Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. . 2021; 19 - 24. 10.14744/scie.2020.24482 |
| IEEE | Okay G,Biberci Keskin E "Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents." , ss.19 - 24, 2021. 10.14744/scie.2020.24482 |
| ISNAD | Okay, Gulay - Biberci Keskin, Elmas. "Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents". (2021), 19-24. https://doi.org/10.14744/scie.2020.24482 |
| APA | Okay G, Biberci Keskin E (2021). Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. Southern Clinics of Istanbul Eurasia, 32(1), 19 - 24. 10.14744/scie.2020.24482 |
| Chicago | Okay Gulay,Biberci Keskin Elmas Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. Southern Clinics of Istanbul Eurasia 32, no.1 (2021): 19 - 24. 10.14744/scie.2020.24482 |
| MLA | Okay Gulay,Biberci Keskin Elmas Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. Southern Clinics of Istanbul Eurasia, vol.32, no.1, 2021, ss.19 - 24. 10.14744/scie.2020.24482 |
| AMA | Okay G,Biberci Keskin E Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. Southern Clinics of Istanbul Eurasia. 2021; 32(1): 19 - 24. 10.14744/scie.2020.24482 |
| Vancouver | Okay G,Biberci Keskin E Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents. Southern Clinics of Istanbul Eurasia. 2021; 32(1): 19 - 24. 10.14744/scie.2020.24482 |
| IEEE | Okay G,Biberci Keskin E "Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents." Southern Clinics of Istanbul Eurasia, 32, ss.19 - 24, 2021. 10.14744/scie.2020.24482 |
| ISNAD | Okay, Gulay - Biberci Keskin, Elmas. "Evaluation of Vaccination Rate and Risk of Infection Among Chronic Inflammatory Disease Patients Receiving Biologic Agents". Southern Clinics of Istanbul Eurasia 32/1 (2021), 19-24. https://doi.org/10.14744/scie.2020.24482 |
